• 东广场：动形通络，功法养生 阳和楼东广场成为动形养生的舞台。专业团队进行《中华通络操》的精彩表演与现场教学，其动作刚柔 并济，犹如疏通人体"络脉"河流，引导气血畅通，吸引众多市民跟随习练，亲身感受"动形"养生的益 处。同时，"养生避坑36计"专家讲堂同步开讲，现场揭秘常见养生误区，如"红枣补血"、"夜跑养 肝"等，提供科学指导，破除迷思。 • 西广场：互动体验，安康祈福 在西广场的安康市集，河北多家医院中医坐镇，提供现场把脉问诊，解答健康疑问；免费健康检测服 务，涵盖睡眠、精力、通络等维度，让人们尽早关注健康状态，提早进行干预；以岭旗下的康养主题酒 店——凯旋门大酒店也精心烹制了健康美味的养生药膳，其融合中医药材、顺应四时、少油低糖、均衡 营养的特点，引得游客们连连称赞。此外，端午民俗与中医药完美结合，艾草香囊DIY、五彩绳结艺、 配制草本养生茶等传统手作体验区人气高涨，市民在趣味互动中深度感知中医药融入生活的文化魅力， 寄托端午安康的美好祈愿。值得一提的是，这里还专门设置了儿童健康角，形成了覆盖全人群、全生命 周期、全流程的中医药健康服务体系。 • 阳和楼二层：主题讲座，健康科普 阳和楼二层化身为静心求 ...

海外专家盛赞中医药抗衰老研究 近日，第五届"亚洲医疗健康高峰论坛"在香港举行，吸引了来自40多个国家和地区的2800多名科研人 员、投资者和企业家线上线下（300959）共同参与，探讨全球医疗健康领域的未来发展与合作机遇。香 港特区行政长官李家超、国家卫生健康委员会副主任曹雪涛院士出席高峰论坛并致辞，世界卫生组织总 干事谭德塞发表视频致辞。 在席卷全球的"银发浪潮"背景下，如何科学抗衰老、实现健康老龄化，成为高峰论坛上最炙手可热的前 沿议题之一。世界中医药学会联合会抗衰老专委会秘书长侯云龙教授在论坛上分享的基于中医气络学说 精气神理论的系列研究——八子补肾胶囊在抗衰老方面的探索与实践，引发了与会各国专家的浓厚兴 趣。 中西医结合推动抗衰老研究新突破 "在国内，60岁及以上人口去年底首次超过了3亿，占总人口22%。衰老带来的各种健康问题越来越突 出。"侯云龙教授在报告开篇点明了研究的现实意义。他介绍，中医理论认为"肾为先天之本"，肾精的 盛衰贯穿人的一生。随着年龄增长，肾精消耗，身体机能就会下降，出现体力变差、记性不好、头发变 白、骨头变脆等衰老现象。 基于此，气络学说精气神理论提出，衰老的核心在于"肾精虚衰" ...

Group 1 - The "2025 China Brand Day Ninth Brand Development Co-Creation Conference" focused on themes of fair competition and brand consumption, gathering industry leaders and experts to discuss brand innovation and sustainable development [1] - The conference highlighted the transformation of Chinese brands from "Made in China" to "Created in China," emphasizing the shift from product output to cultural output [2] - The demand for traditional Chinese medicine (TCM) is growing due to increased health awareness, but TCM brands face challenges in distinguishing themselves in modern medical competition and international markets [4] Group 2 - Cultural confidence is a lasting force in national development, with TCM recognized globally as a treasure of Chinese civilization, leading to increased international attention and validation of its theoretical value [5] - Yiling Pharmaceutical, a leading innovative TCM company, has developed the Ba Zi Bu Shen capsule, which meets international scientific standards and promotes the integration of TCM evaluation systems with global practices [5] - The Ba Zi research team has collaborated with international medical research institutions, publishing nearly 20 high-quality SCI articles to enhance the brand's presence among professional audiences [5] Group 3 - Chinese brands, including TCM, are gaining recognition on the global stage, with Ba Zi Bu Shen approved for sale in eight countries, including Canada and Singapore, and available on major cross-border platforms [7] - The international success of TCM products like Ba Zi Bu Shen contributes to the promotion of TCM's influence abroad and fosters dialogue between Eastern and Western medicine [7]

以岭药业 20250429 摘要 • 以岭药业 2025 年一季度营收 23.58 亿元，同比下降 6.5%，归母净利润 3.26 亿元，同比增长 7.25%，经营性净现金流 3.4 亿元，同比增长 190%。应收账款周转天数同比下降 35 天，经营质量初步提升。 • 连花清瘟产品一季度销售同比增长近 30%，心脑血管处方药受政策影响有 所下滑，但预计二季度将逐步恢复性增长。二线品种如静神胶囊、复方丹 参片等开户工作稳步推进，OTC 品种八子补肾胶囊加大推广力度。 • 健康科技板块重点推广蓝帽子保健食品及功能性植物饮料，怡梦饮料单品 销售超 1.2 亿，调节血糖饮料精力旺销售额超 5,000 万，市场前景良好。 • 公司研发方面，治疗糖尿病视网膜病变的明目胶囊进入医保，治疗过敏性 鼻炎的芪芳鼻通片获批上市，六个品种处于临床阶段，小儿连花清瘟颗粒 处于三期临床。五项循证医学研究成果发表在国际顶刊。 • 化学生物板块有四个创新药进入临床阶段，多个一类创新药处于临床前验 证阶段，百乐宁已报产，SY0,206 片用于急性髓性白血病治疗已进入三期 临床研究。 Q&A 2024 年以岭药业的营业收入和净利润情况如何？ 2 ...

Core Viewpoint - Yiling Pharmaceutical reported a net loss for 2024 due to revenue reduction from expiring respiratory products and increased inventory impairment, but maintains high R&D investment levels, with over 900 million yuan allocated, representing 13.94% of revenue, which is leading in the industry [1][5]. R&D Investment - Yiling Pharmaceutical has a strong R&D capability based on its unique theory of network disease, which has led to a nearly 25-fold increase in R&D investment since 2008 [2]. - The company continues to maintain high R&D investment levels, with 900 million yuan in 2024, ranking among the top in the industry [5]. Product Development and Pipeline - The company has 17 patented new drugs, with 11 included in the national medical insurance directory and 5 in the national essential drug list [5]. - Yiling Pharmaceutical has ongoing registration applications for two innovative traditional Chinese medicine products and three chemical drug products, enhancing its product pipeline [6]. Market Performance - Yiling Pharmaceutical's respiratory and cardiovascular products lead their respective markets, with Lianhua Qingwen capturing 24.36% of the cold medicine market in public healthcare [7]. - The company’s core cardiovascular products hold a combined market share of 17.69% in the public healthcare sector [7]. New Growth Areas - The company is expanding into the health and wellness sector, with products targeting blood lipid regulation, sleep improvement, and blood sugar control [8]. - Yiling Pharmaceutical's OTC product Baizi Bujin Capsule is highlighted as a potential new pillar product, supported by extensive evidence from clinical studies [8].